干扰素β对多发性硬化症患者生活质量的影响:系统性审查和元分析研究
Mohammadreza Jamshidi1, Milad Abbasian2, Ali Ghasemnezhad3
1Department of Anesthesiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Current journal of neurology
|April 15, 2025
概括
对多发性硬化症 (MS) 的干扰素β (IFN-β) 治疗不会对患者的生活质量 (QOL) 产生负面影响. 这一元分析表明,在接受IFN-β.的MS患者中,大多数QOL尺度,特别是身体和精神组件略有改善.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 是一种常见的进展性神经系统疾病,影响年轻成年人.
- 干扰素β (IFN-β) 是用于MS治疗的治疗剂.
- IFN-β对MS患者的生活质量 (QOL) 的影响需要全面分析.
研究的目的:
- 进行元分析,评估干扰素β (IFN-β) 对多发性硬化症 (MS) 患者的生活质量 (QOL) 的影响.
- 综合现有文献的发现,以提供IFN-β对MS的质量生活影响的可靠评估.
主要方法:
- 在数据库 (Medlib,ScienceDirect,PubMed) 中进行了系统的文献搜索,搜索了1999年至2020年间发表的研究.
- 纳入标准侧重于接受IFN-β治疗的成年MS患者,测量QOL结果,并排除非英语,儿科或非对照研究.
- 使用R和Stata软件使用随机效应模型元分析,通过Q测试和I2指数评估异质性;在异质研究中使用子组分析和元回归.
主要成果:
- 分析包括1320名患者 (平均年龄为32.40±8.77岁).
- 虽然能量和性功能尺度略有下降,但其他12个QOL尺度略有改善.
- 在健康困扰 (HD),由于身体问题而导致的角色限制 (RLPP) 和由于情绪问题而导致的角色限制 (RLEP) 中观察到显著改善.
- 身体和精神成分得分分别显著增加了0.189 (95% CI:0.083,0.295) 和0.221 (95% CI:0.119,0.324).
结论:
- 用贝塔干扰素 (IFN-β) 治疗不会对患有多发性硬化症 (MS) 的患者的生活质量 (QOL) 产生不利影响.
- IFN-β治疗表明能够略微提高大多数QOL尺度,特别是与MS体验的残疾相关的尺度.
更多相关视频
10:00High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
13.3K
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
12.1K
相关概念视频
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.